FOR IMMEDIATE RELEASE
- New product line targets permitted markets outside the United States, led by Latin America and Southeast Asia
- Launch extends Cellgenic’s cellular-technology portfolio into immunology-adjacent applications
- Natural killer cell platform positions Cellgenic within a growing category of advanced cellular science
MIAMI, FL — Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced the launch of a Natural Killer (NK) cell product line for permitted markets outside the United States, with an initial commercial focus on Latin America and Southeast Asia.
NK cells are a class of cytotoxic lymphocytes with a growing body of research interest across immunology and cellular-science applications. Cellgenic’s new product line broadens the Company’s cellular-technology offering to physicians and clinics operating under the regulatory frameworks of its target markets.
The Company said international demand for advanced cellular and immunology-related technologies has continued to grow, and that the NK cell launch reflects Cellgenic’s broader strategy of expanding its product portfolio to meet physician demand in permitted markets.
“Natural killer cell technology represents one of the more active areas of interest in cellular science today,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “Adding an NK cell product line lets Cellgenic meet physician demand we’re already seeing internationally, and it’s a natural extension of the cellular-technology platform we’ve built.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About Cellgenic
Cellgenic, the biotechnology and product-commercialization division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), develops and distributes advanced cellular technologies, biologics, peptide therapeutics, and related regenerative-medicine products to physicians and clinics in permitted international markets.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact
Investor contact: info@stemcellsgroup.com
Media contact: info@stemcellsgroup.com
